Abstract
A class of potent, selective adenosine A3 receptor antagonists was obtained via optimisation of the screening hit N-[4-(4-methoxyphenyl)-thiazol-2-yl]-acetamide. Structural modifications of this hit revealed very quickly that a 5-(pyridin-4-yl) substituent on the 2- aminothiazole ring was optimal for high potency at the adenosine A3 receptor. Structure activity relationship studies led to both potent and selective A3 receptor antagonists, including N-[5-pyridin-4-yl-4-(3,4,5-trimethoxyphenyl)-thiazol-2-yl]-acetamide, a highly potent aden-osine A3 receptor antagonist with greater than 100- fold selectivity against the related adenosine receptors. As well as demonstrating selective in vitro binding on the human A3 adenosine receptor, this compound was also shown to selectively block the rat A3 receptor in vivo. This important new compound can be readily synthesised in four steps from commercially available starting materials.
Keywords: adenosine a3 receptor antagonists, n-[4-(4-methoxyphenyl)-thiazol-2-yl]-acetamide, n-[5-pyridin-4-yl-4-(3,4,5-trimethoxyphenyl)-thiazol-2-yl]-acetamide
Current Topics in Medicinal Chemistry
Title: New Highly Potent and Selective Adenosine A3 Receptor Antagonists
Volume: 4 Issue: 8
Author(s): Neil J. Press, Thomas H. Keller, Pamela Tranter, David Beer, Ken Jones, Alexander Faessler, Richard Heng, Christine Lewis, Trevor Howe and Peter Gedeck
Affiliation:
Keywords: adenosine a3 receptor antagonists, n-[4-(4-methoxyphenyl)-thiazol-2-yl]-acetamide, n-[5-pyridin-4-yl-4-(3,4,5-trimethoxyphenyl)-thiazol-2-yl]-acetamide
Abstract: A class of potent, selective adenosine A3 receptor antagonists was obtained via optimisation of the screening hit N-[4-(4-methoxyphenyl)-thiazol-2-yl]-acetamide. Structural modifications of this hit revealed very quickly that a 5-(pyridin-4-yl) substituent on the 2- aminothiazole ring was optimal for high potency at the adenosine A3 receptor. Structure activity relationship studies led to both potent and selective A3 receptor antagonists, including N-[5-pyridin-4-yl-4-(3,4,5-trimethoxyphenyl)-thiazol-2-yl]-acetamide, a highly potent aden-osine A3 receptor antagonist with greater than 100- fold selectivity against the related adenosine receptors. As well as demonstrating selective in vitro binding on the human A3 adenosine receptor, this compound was also shown to selectively block the rat A3 receptor in vivo. This important new compound can be readily synthesised in four steps from commercially available starting materials.
Export Options
About this article
Cite this article as:
Press J. Neil, Keller H. Thomas, Tranter Pamela, Beer David, Jones Ken, Faessler Alexander, Heng Richard, Lewis Christine, Howe Trevor and Gedeck Peter, New Highly Potent and Selective Adenosine A3 Receptor Antagonists, Current Topics in Medicinal Chemistry 2004; 4 (8) . https://dx.doi.org/10.2174/1568026043451023
DOI https://dx.doi.org/10.2174/1568026043451023 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bioactive Peptides in Preventative Healthcare: An Overview of Bioactivities and Suggested Methods to Assess Potential Applications
Current Pharmaceutical Design Vascularization of Engineered Tissues: Approaches to Promote Angiogenesis in Biomaterials
Current Topics in Medicinal Chemistry CB Receptor Ligands from Plants
Current Topics in Medicinal Chemistry Tumor Necrosis Factor: How to Make a Killer Molecule Tumor-Specific?
Current Cancer Drug Targets Targeted Gene Deletion of Prolyl Hydroxylase Domain Protein 3 Triggers Angiogenesis and Preserves Cardiac Function by Stabilizing Hypoxia Inducible Factor 1 Alpha Following Myocardial Infarction
Current Pharmaceutical Design Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar
Current Vascular Pharmacology Annona sp: Plants with Multiple Applications as Alternative Medicine - A Review
Current Bioactive Compounds Non-dipping Status in Arterial Hypertension: An Overview
Current Vascular Pharmacology Rapid Desensitization of Hypersensitivity Reactions to Chemotherapy Agents.
Current Drug Safety Acute Myocarditis in Children: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Citric Acid: A Green Bioorganic Catalyst for One-Pot Three-Component Synthesis of 2,3-dihydroquinazoline-4 (1H)-ones
Current Organocatalysis Evaluation of Allergic Reactions Following Intravenous Infusion of Polyvalent Antivenom in Snakebite Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Sodium Carbonate Sesquiperhydrate (2Na2CO3-3H2O2) Catalysed One-pot Synthesis of Biologically Dynamic Novel Substituted Spirooxirane Dicarboxamides
Current Catalysis A Study of the Relaxed Mechanisms Induced by Novokinin in the Isolated Porcine Coronary Artery Ring Segments
Protein & Peptide Letters Pharmacological Effects of Biotin in Animals
Mini-Reviews in Medicinal Chemistry Food Allergy
Current Pharmaceutical Design Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: A New Cause of Hypertension
Current Hypertension Reviews Weight Loss in Obesity and Metabolic Syndrome
Current Hypertension Reviews High-output Cardiac Failure: A Forgotten Phenotype in Clinical Practice
Current Cardiology Reviews Acute Kidney Injury: Turning the Tide
Current Drug Targets